Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U6BQ
|
|||
| Former ID |
DIB001919
|
|||
| Drug Name |
Anti-VEGFR2 CD8 cell therapy
|
|||
| Synonyms |
Anti-VEGFR2 CD8 cell therapy (cancer)
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Company |
Pervasis Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.